


Automation on RaySearch

ICTP School of Medical Physics for Radiation Therapy:
Dosimetry and Treatment
Planning for Basic and Advanced Applications
12 September 2025
Trieste



Christian Fiandra, PhD



RayStation infrastructure

Citta della Salute e della Scienza, Turin, Italy

Three hospitals

S. Giovanni



Molinette



S. Anna



5 Versa HD



RayStation server



Radixact

First automation step: Images loading e contouring

Create patient in the
database with images and
structures

Philips CT Big Bore



Tag Dicom (0018,1030)	Structure template RayStation
STANDARD/TECSPEC	
STEREO ENC 1.5 mm/TECSPEC	Brain_Template and Couch_SRS_Template
ENC 3 mm Vol/TECSPEC	Brain_Template
TESTACOLL 2 mm Vol./TECSPEC	HN_Template
Pulm Gating 4D PRO/TECSPEC	Lung_Template
LIVER Gating 4D PRO/TECSPEC	Liver_Template
FEGATO 4D SEMI 2 mm/TECSPEC	Liver_Template
FEGATO / SURRENE NO 4D/TECSPEC	Liver_Template
TORACE 3 mm/TECSPEC	Lung_Template
SBRT VERTEBRATORACICHE/TECSPEC	Lung_Template
TORACE 3 mm ESOFAGO/TECSPEC	Esoph_Template
TORACE 3 mm LINFOMA/TECSPEC	LIMP_Template
ABLAZIONE CARDIACA/TECSPEC	Lung_Template
MAMMELLA 3 mm/TECSPEC	BREAST_Template
MAMMELLA 3 mm C-PAP/TECSPEC	BREAST_Template
PELVI 3 mm PROSTATA/TECSPEC	PROSTATE_Template
PROSTATA IPO TOMO 2mm/TECSPEC	PROSTATE_Template
PELVI 3 mm/TECSPEC	Rectum_Template
SBRT VERTEBRALOMBARE/TECSPEC	Rectum_Template
T.M.I. 5mm/TECSPEC	TMI/TMLI_Template
T.M.L.I. 5mm/TECSPEC	TMI/TMLI_Template
MEDULLO 3 mm/TECSPEC	TMI/TMLI_Template
T.B.I. 5 mm/TECSPEC	TBI_Template

First automation step Images loading e contouring

Dicom

(0018,0090)	Data Collection Diameter	Keep	600
(0018,1020)	Software version(s)	Keep	2.3.0
(0018,1030)	Protocol Name	Keep	STEREO enc 1,5 mm/TECSPEC
(0018,1100)	Reconstruction Diameter	Keep	600

Database creation

Open case

Search: Primary database only

Patient and case						
	Last name	First name	Patient ID	Physician	Body site	Last saved (DD MMM YYYY, hr:min:sec)
●	GERBI	LUGI	GRBLOU47806...	PARISE	RETRO	02 Sep 2025, 10:34:31
●	GEUNA	GEMMA	GNEGMM598...	BADELLINO	POLMONE DX	04 Sep 2025, 13:52:39
●	GIACOVELLI	SABELLA	GOVSL15153E...	-	-	02 Sep 2024, 11:32:14
●	HERTEL	PIO CESARE ER...	HRTPSR56A09...	CAVALLIN	PARETE TORAC...	29 Aug 2025, 15:10:10
●	JIGA	DANIELA	JGIDNL73763Z...	LEVIS	ENCEFALO	04 Sep 2025, 18:50:23
●	LA MARCA	MICHELE	LMRMHL639D...	CERRATO	PEGATO	04 Sep 2025, 14:53:33
●	LAMAINA	LORENZO	LMNLNL25A1...	GASTINO	EMBACINO SX	15 Jul 2025, 09:17:00
●	LIBERTONE	CLAUDIO	LBRLD62E2OL...	CERRATO	MEDIASTINO	03 Sep 2025, 14:09:46
●	LO PUNO	FRANCESCO	LPFRNC330D...	PARISE	PROSTATIA	04 Sep 2025, 13:22:07
●	LUO	SHAOMAO	LUOSHM63CS...	CASALE	FRONTALE DX	03 Sep 2025, 10:28:59

Plan

	Name	Last saved (DD MMM YYYY, hr:min:sec)
■	1.1	04 Sep 2025, 13:22:07
■	Bench_1.1	04 Sep 2025, 12:31:48
■	Empty plan	04 Sep 2025, 12:31:48

Patient details

Gender: Male
Date of birth:
Planned image set(s): TC 26/08/2025, TC 09/08/2023, CT 1

Beam sets

Name	Dose type
1.1	Clinical: Collapsed Cone v5.10

Open Cancel

Structures template

Create structures from template

Template: HN_Template

Initialization

Align image centers

Image sets

Name	Mod...	No. of pixels	Pixel size(cm)
CT 1	CT	512 512 199	0.117 0.117

Structures

When name of template structure matches name of existing target structure:

☒ Update existing structure if it is not already defined
☐ Create new structure

External ROI: -
Localization point: -

ROIs		POIs		
Name	Type	Material	Initialization method	Representati...
External	External		Auto-generated external	Contours (tran...
Lung_R	Organ		Empty geometry	Empty
Lung_L	Organ		Empty geometry	Empty
Cavity_Oral	Organ		Empty geometry	Empty
Parotid_R	Organ		Empty geometry	Empty
Parotid_L	Organ		Empty geometry	Empty
Globd_Thyroid	Organ		Empty geometry	Empty

Deep learning segmentation will be used for all applicable ROIs.

☒ Update derived ROIs

OK Cancel

Deep learning segmentation

Primary image set

CT: TC 26/08/2025 [26 Aug 2025, 12:43:43 (hr:min:sec)]


Select model ROI(s) (0 of 123 selected)

- ☐ RSL DLS CT
 - ☐ Abdomen
 - ☐ Breast
 - ☐ Head and neck
 - ☐ Pelvic male
 - ☐ Thorax
 - ☐ Vessels

Second automation step Planning




MCO



RayStation Plan Explorer



Guided Planning Solution



Elekta ONE®
Planning



M-cycle



AAPM REPORT NO. 263



Standardizing Nomenclatures in Radiation Oncology

**The Report of AAPM
Task Group 263**

January 2018

Standardization is key to improve script-based plan evaluation
Reduce variability and inconsistencies

HN

☐	☒ External
☐	☒ Brainstem
☐	☒ Brainstem_PRV
☐	☒ SpinalCord
☐	☒ SpinalCord_PRV
☐	☒ Parotid_R
☐	☒ Parotid_L
☐	☒ Cavity_Oral
☐	☒ Mandible
☐	☒ Cochlea_R
☐	☒ Cochlea_L
☐	☒ GInd_Thyroid

Prostate

☐	▲ Organs at risk (16)
☐	☒ External
☐	☒ Femur_Head_R
☐	☒ Femur_Head_L
☐	☒ Bladder
☐	☒ Rectum
☐	☒ PenileBulb
☐	☒ Bowel_Small

Breast

☐	▲ Organs at risk (23)
☐	☒ External
☐	☒ Breast_L
☐	☒ A_LAD
☐	☒ Heart
☐	☒ Lung_L
☐	☒ Lung_R

SBRT Lung

☐	▲ Organs at risk (18)
☐	☒ BODY
☐	☒ Trachea_Bronchus
☐	☒ SpinalCord
☐	☒ Lung_R
☐	☒ Lung_L
☐	☒ ChestWall
☐	☒ Esophagus
☐	☒ Heart
☐	☒ EsophagusPRV
☐	☒ BronchITree_LPRV
☐	☒ Lungs-PTV

Edit OAR Names

Current ROI

Model ROI

SpinalCanal

PRV MIDOLLO

BrachialPlex_L

BrachialPlex_R

Breast_R

Esophagus

Esophagus_S


GInd_Thyroid

Matched OARs: 5/7 (71.4%)

Cancel

Save

Genetic Planning Solution – GPS



GPS

OARs

PTV

$$EUD = \left(\frac{1}{N} \sum_{i=1}^N d_i^a \right)^{\frac{1}{a}}$$

where:

- N = number of voxels (or dose bins) in the structure
- d_i = dose in voxel i
- a = tissue-specific parameter
 - **Negative a** → makes the calculation tumor-control-oriented (focuses on underdosed regions)
 - **Positive a** → makes the calculation normal-tissue-oriented (focuses on hotspots)
 - $a \rightarrow \infty \rightarrow$ EUD approaches the maximum dose
 - $a = 1 \rightarrow$ EUD becomes the mean dose




Max EUD		Plan	 Femur_Head_R	Max EUD 685 cGy, Parameter A 1
Max EUD		Plan	 Femur_Head_L	Max EUD 765 cGy, Parameter A 1
Max EUD		Plan	 Bladder1	Max EUD 1611 cGy, Parameter A 1
Max EUD		Plan	 Rectum1	Max EUD 1464 cGy, Parameter A 1
Max dose		Plan	 Bowel_Small	Max dose 5000 cGy
Max EUD		Plan	 Bowel_Small	Max EUD 4000 cGy, Parameter A 10
Max EUD		Plan	 Bowel_Small1	Max EUD 477 cGy, Parameter A 1
Max EUD		Plan	 PenileBulb1	Max EUD 1946 cGy, Parameter A 20



Genetic Planning Solution 2.2

Genetic algorithm



Same fitness function for all centers
no center-specific tuning is applied!!

Bladder1 Max EUD 9.00 Gy, Parameter A 1
Rectum1 Max EUD 18.00 Gy, Parameter A 1



A genetic algorithm was implemented in the RayStation treatment planning system (Version 8A) using Python code inside a platform called Genetic Planning Solution

Heuristic Optimization - Genetic Algorithm



International Journal of Medical Physics, Clinical Engineering and Radiation Oncology, 2018, 7, 414-421
<http://www.scirp.org/journal/ijmpro>
ISSN Online: 2158-5484
ISSN Print: 2158-5436

Automated Heuristic Optimization of Prostate VMAT Treatment Planning

Christian Fianstra¹, Alessandro Alparone², Elena Gallo³, Claudio Vecchi⁴,
Gabriella Balestra⁵, Sara Bartocci⁶, Samanta Rosati⁷, Riccardo Ragone⁸,
Umberto Ricardi⁹

¹Department of Oncology, Radiation Oncology, University of Turin, Turin, Italy
²Technologie Avancée T.A. 54, Turin, Italy
³Medical Physics Unit, A.O.U. Città della Salute e della Scienza, Turin, Italy
⁴Department of Electronics and Telecommunications, Politecnico di Torino, Turin, Italy
⁵Radiation Oncology Unit, A.O.U. Città della Salute e della Scienza, Turin, Italy
Email: christian.fianstra@unito.it

GAs are a particular class of evolutionary algorithms that use techniques inspired by evolutionary biology such as inheritance, mutation, selection, and crossover (also called recombination)

Abstract

Purpose: To investigate a genetic algorithm approach to automatic treatment planning. **Methods:** A Python script based on genetic algorithm (GA) was implemented for VMAT treatment planning of prostate tumor. The script was implemented in RayStation treatment planning system using Python code. Two different clinical prescriptions were considered: 78 Gy prescribed to planning target volume in 39 fractions (GROUP 1) and simultaneous integrated boost (70.2 Gy to prostate bed and 41.1 Gy to seminal vesicles) in 26 fractions (GROUP 2). The script automatically optimizes doses to PTV and OARs according to GA. A comparison with corresponding plans created with Monaco TPS (M) and Auto-Planning module of Pinnacle³ (AP) was carried out. The plans were evaluated with a total score (TS) of PlanIQ software in terms of target coverage and sparing of OARs as well as clinical score (CS) performed by a Radiation Oncologist. **Results:** In GROUP 1, mean value of TS were 130.6 ± 30.7, 146.3 ± 36.1 and 137.4 ± 35.7 for AP, GA and M respectively. For GROUP 2, mean value for TS were 163.5 ± 14.8, 163.4 ± 24.7 and 162.9 ± 16.6 for AP, GA and M respectively with no significance differences. In terms of CS, the highest value has been attributed to GA in four patients out of five for both GROUP 1 and 2. **Conclusions:** Genetic approach is practicable for prostate VMAT plan generation and studies are underway in other anatomical sites such as Head and Neck and Rectum.

AAPM REPORT NO. 263



Standardizing Nomenclatures in Radiation Oncology

The Report of AAPM
Task Group 263

January 2018

VMAT Prostate radiotherapy treatment planning

10 participating Italian centers

10 prostate patients

manually generated Vs AutoGPS




100 Manual plans

centers

patients

	A	B	C	D	E	F	G	H	I	J
1										
2										
3										
4										
5										
6										
7										
8										
9										
10										



100 AutoGPS plans

centers


patients

	A	B	C	D	E	F	G	H	I	J
1										
2										
3										
4										
5										
6										
7										
8										
9										
10										

Vs



GPS in clinical practice – prostate



Radiotherapy and Oncology 148 (2020) 126–132

Contents lists available at ScienceDirect

Radiotherapy and Oncology

journal homepage: www.thegreenjournal.com

Original Article

Automatic genetic planning for volumetric modulated arc therapy:
A large multi-centre validation for prostate cancer

Christian Fiandra^{a,b,*}, Linda Rossi^c, Alessandro Alparone^d, Stefania Zara^d, Claudio Vecchi^d, Anna Sardo^e, Sara Bartoncini^f, Gianfranco Loi^g, Carla Pisani^h, Eva Ginoⁱ, Maria Grazia Ruvo Redda^j, Gian Marco Deotto^k, Paolo Tini^l, Stefania Comi^m, Dario Zeriniⁿ, Gianluca Ametrano^o, Valentina Borzillo^o, Lidia Strigari^{p,1}, Silvia Strolin^{p,1}, Alessandro Savini^q, Antonino Romeo^r, Sonia Reccanello^s, Imad Abu Rumeileh^t, Nunzia Ciscognetti^u, Flavia Guerrisi^v, Gabriella Balestra^w, Umberto Ricardi^x, Ben Heijmen^c



Validation

Which is the better plan?

1



2



1 ———

2 - - - - -




or





Validation

Which is the better plan?

1



2



1

or

2




Multi-centre prostate



Manual Vs Auto




Clinical blind comparison (CBS)




GPS in clinical practice – Prostate

Clinical Blind Score




Dosimetric OAR parameters



GPS in clinical practice – prostate



- **Goal:** Validate a single-configuration genetic autoplanning system (GPS) for prostate VMAT across 10 centres.
- **Key results:**
 - 91% of autoGPS plans were clinically acceptable.
 - 69% of acceptable plans were preferred over manual ones.
 - Better rectum/bladder sparing with similar PTV coverage.
- **Variability:**
 - Inter-centre differences linked to protocol mismatch and manual plan quality.
 - GPS could help standardize plan quality across centres.
- **Centre H issue:** Solved by minor configuration adjustment to match local coverage criteria.
- **Strengths & implications:**
 - Largest multi-centre autoplanning validation to date.
 - Shows potential to reduce workload, improve quality, and avoid centre-specific tuning.
- **Limitations:** Small sample per centre and QA checks done only in one centre

GPS 4.2



GPS 4.2

Benchmark dose



Patient specific optimization function

Function	Constraint	Dose	ROI	Description
Physical composite objective				
Min DVH		Plan	PTV_Breast	Min DVH 4005 cGy to 100% volume
Max DVH		Plan	PTV_Breast	Max DVH 4285 cGy to 2% volume
Max dose		Plan	PTV_Breast	Max dose 4406 cGy
Max EUD		Plan	ring1.PTV somma	Max EUD 2804 cGy, Parameter A 20
Dose fall-off		Plan	ring1.PTV somma	Dose fall-off [H]4005 cGy [L]1602 cGy,
Uniform dose		Plan	PTV_Breast	Uniform dose 4005 cGy
Dose fall-off		Plan	Ext1	Dose fall-off [H]4005 cGy [L]801 cGy, t
Dose fall-off		Plan	Ext2	Dose fall-off [H]401 cGy [L]80 cGy, Low
Max EUD		Plan	GInd_Thyroid	Max EUD 4830 cGy, Parameter A 20
Max EUD		Plan	Liver	Max EUD 463 cGy, Parameter A 20
Max EUD		Plan	Breast_L	Max EUD 168 cGy, Parameter A 20
Max EUD		Plan	Lung_L	Max EUD 100 cGy, Parameter A 1
Max EUD		Plan	Medial_Region	Max EUD 1602 cGy, Parameter A 20
Max EUD		Plan	Dummy1	Max EUD 1602 cGy, Parameter A 20
Max EUD		Plan	Lung_R1	Max EUD 296 cGy, Parameter A 1
Max EUD		Plan	Heart	Max EUD 50 cGy, Parameter A 1

A method for *a priori* estimation of best feasible DVH for organs-at-risk: Validation for head and neck VMAT planning

Saeed Ahmed
Department of Physics, University of South Florida, Tampa, FL 33612, USA

Benjamin Nelms
Canis Lupus LLC, Merrimac, WI 53561, USA

Dawn Gintz, Jimmy Caudell, Geoffrey Zhang, Eduardo G. Moros, and Vladimir Feygelman^{a)}
Department of Radiation Oncology, Moffitt Cancer Center, Tampa, FL 33612, USA

(Received 27 March 2017; revised 24 July 2017; accepted for publication 24 July 2017; published 31 August 2017)

Benchmark dose



1. Generation of a **D₀** dose grid of the required resolution, the values are given by the **dose prescribed** to the target(s) within the target(s) and zero outside.
2. Generation of a **D₁** dose grid, the DO dose is evolved applying to each axial plane a series of convolutions through symmetrical kernels that take into account the Low-Gradient Dose Spread component both at mid-range and far-range.

$$\mathbf{D1[y][x,z]} = (\mathbf{D_0[y][x,z]} * \mathbf{LGDS-Mid_E[x,z]}) * \mathbf{LGDS-Far_E[x,z]}$$





3. Generation of a **D₂** dose grid, the DO dose is evolved outside the target(s) assigning to each voxel external to the target(s) the value given by the maximum diffuse value searched among all the nearby target voxels:

$$\mathbf{D2[x,y,x]} = \max(\mathbf{x_T,y_T,z_T}) \{ \mathbf{D0[x_T,y_T,z_T]} \times \mathbf{HGDS_E[r,r_{rad}]} \}$$

Where $\mathbf{HGDS_E[r,r_{rad}]}$ is the High-Gradient Dose Spread function for a given beam energy E , $\mathbf{r}$ is the physical distance between the voxel to be filled $[x,y,z]$ and the target voxel $[x_T,y_T,z_T]$, and $\mathbf{r_{rad}}$ is the corresponding radiological distance calculated as the line integral of the density extracted from the CT associated with the study.


4. **Combination of doses D₀, D₁ e D₂ into a dose D** defined as:

$$\mathbf{D[x,y,z]} = \max (\mathbf{D1 [x,y,z]}, \mathbf{D2 [x,y,z]}, \mathbf{D3 [x,y,z]})$$



Benchmark dose

Standard parameters





Optimized parameters






- 24 centres
- 10 patients / centre
- 240 patients



Supraclavicular LNF



Physica Medica 123 (2024) 103394

Contents lists available at ScienceDirect

Physica Medica

journal homepage: www.elsevier.com/locate/ejmp




Original paper


Multi-centre real-world validation of automated treatment planning for breast radiotherapy

C. Fiandra^{a,*}, S. Zara^b, V. Richetto^c, L. Rossi^d, M.C. Leonardi^e, P. Ferrari^f, M. Marrocco^g, E. Gino^h, S. Coraⁱ, G. Loi^j, F. Rosica^k, S. Ren Kaiser^l, E. Verdolino^m, L. Strigariⁿ, N. Romeo^o, L. Placidi^p, S. Comi^q, G. De Otto^r, A. Roggio^s, A. Di Dio^t, L. Reversi^u, E. Pierpaoli^v, E. Infusino^w, E. Coeli^x, T. Licciardello^x, A. Ciarmatori^y, R. Caivano^z, A. Poggiu^{aa}, N. Ciscognetti^{bb}, U. Ricardi^a, B. Heijmen^{ci}







- 24 centres
- 10 patients / centre
- 240 patients



Study design




Results: CBS1



Clinical preferences

All plans were
clinically acceptable


No centre specific
configuration




■ Auto ■ Manual ■ Parity

Results: DVH comparison


OARs



Heart




Left anterior descending coronary artery




Results: DVH comparison


OARs




Contralateral breast




Lungs




Results: PSQA comparison





Monitor Units



GPR (3% 2mm global)



GPS in clinical practice – breast



Conclusion multicentre breast

Purpose: Evaluate a multicentre protocol for breast cancer radiotherapy to ensure reproducibility and plan quality across institutions.



Main Findings: Good consistency in plan quality among centres despite different TPS and planners. Dose constraints for target coverage and OAR sparing were largely met. Variability observed in some dosimetric parameters, but all within clinically acceptable ranges. Inter-centre Variability: Small differences attributed to planner experience, contouring variability, and TPS optimization strategies demonstrates feasibility of harmonizing breast cancer RT planning across centres.

Strengths: Multicentre design provides strong evidence for protocol reproducibility. Highlights value of shared guidelines and centralized review for quality assurance.

Limitations: limited number of patients per centre may not capture all sources of variability. Further standardization of contouring and plan optimization may further reduce variability.

Implications: Results support implementation of shared planning protocols for clinical trials and cooperative studies. Central review and feedback loops are important to maintain consistency over time.

GPS in clinical practice - SBRT



Priority	
1	
1	
1	
1	
2	
2	
2	
2	
3	
4	

ROI/POI		Clinical goal
GPS5_Auto...	PTV1.1	At least 2850 cGy dose at 95.00 % volume
GPS5_Auto...	PTV1.1	At least a conformity index of 0.25 at 1500 cGy isodose
GPS5_Auto...	PTV1.1	At most 2.00 % volume at 3210 cGy dose
GPS5_Auto...	Breasts	At most 400 cGy average dose
GPS5_Auto...	Heart	At most 500 cGy average dose
GPS5_Auto...	Lungs-PTV	At most 2000 cGy dose at 20.00 % volume
GPS5_Auto...	Lungs-PTV	At most 500 cGy dose at 50.00 % volume
GPS5_Auto...	Heart	At most 300 cGy average dose




GPS in clinical practice – SBRT




Manual Planning

20 lung SBRT cases (10 peripheral: 60 Gy/5 fx, 10 central: 60 Gy/8 fx).
VMAT (2–4 coplanar arcs, 6 MV FFF), Eclipse v15.6.
 $D2\% \leq 72$ Gy, $D98\% \geq 54$ Gy, ITV Dmean ≥ 65 Gy.
AAA algorithm, 1.25 mm grid.



Automatic Planning (AP)

Guided Planning System (GPS) in RayStation v12A.
Same machine, arcs, isocenter as MP; CCC algorithm, 1.2 mm grid.




Quality Assurance

SRS MapCHECK + StereoPHAN phantom, 2%/2 mm gamma ($\geq 90\%$ pass).

Plan Comparison

DVH metrics, clinician blind review, gamma pass rate, MUs.
Plan quality metrics: Conformation Number, Homogeneity Index, Gradient Index.



GPS in clinical practice – SBRT





Fig. 3. Clinician's blind comparison results for (a) 5 and (b) 8 fractions scheme.

Conclusion GPS - SBRT

- *Automatic planning (AP) matched or outperformed manual planning (MP) in plan quality and consistency for lung SBRT.*
- *Clinician review confirmed AP plans were clinically acceptable in most cases (equal or better in 65%).*
- *AP reduces inter-planner variability and saves time, serving as a strong starting point for planning. AP plans still **require** review and possible refinement before delivery.*
- *The center now uses GPS autoplanning routinely for lung SBRT and is validating it for other tumor sites*

Automation in RaySearch Summary

- GPS may be considered as an advanced starting point for planning
 - *reduces inter-planner variability, saves time, harmonize optimization strategy serving as a strong starting point but **require** review and possible refinement before delivery*

GPS autopanning routinely used in 30 centres across Italian country



ICTP The Abdus Salam
International Centre
for Theoretical Physics

United Nations
Educational, Scientific and
Cultural Organization

IAEA
International Atomic Energy Agency

Research ▾

Educating thousands of scientists from around the world